Bros. Advisors Lp Baker Acquires 985,397 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker bought 985,397 shares of the company’s stock in a transaction on Friday, December 13th. The shares were acquired at an average cost of $13.76 per share, for a total transaction of $13,559,062.72. Following the completion of the acquisition, the director now directly owns 9,537,643 shares of the company’s stock, valued at $131,237,967.68. This trade represents a 11.52 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, December 16th, Bros. Advisors Lp Baker purchased 500,000 shares of Bicycle Therapeutics stock. The stock was acquired at an average cost of $15.34 per share, with a total value of $7,670,000.00.

Bicycle Therapeutics Stock Performance

NASDAQ:BCYC opened at $15.31 on Thursday. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of -4.65 and a beta of 0.86. Bicycle Therapeutics plc has a 1 year low of $12.17 and a 1 year high of $28.67. The business has a fifty day moving average of $22.45 and a 200-day moving average of $22.66.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The firm had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s revenue was down 50.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.26) EPS. On average, equities research analysts predict that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BCYC. FMR LLC acquired a new stake in Bicycle Therapeutics in the third quarter worth approximately $3,406,000. TD Asset Management Inc lifted its holdings in shares of Bicycle Therapeutics by 76.7% in the second quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after buying an additional 42,200 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Bicycle Therapeutics by 33.2% during the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after buying an additional 32,313 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Bicycle Therapeutics during the second quarter worth about $11,577,000. Finally, Renaissance Technologies LLC raised its position in Bicycle Therapeutics by 97.2% in the second quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after acquiring an additional 161,100 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BCYC has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. JMP Securities cut their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday. HC Wainwright lowered their price objective on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research note on Monday. B. Riley cut their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Finally, Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Bicycle Therapeutics has an average rating of “Moderate Buy” and an average price target of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.